Skip to main content

Advertisement

Table 2 Chemotherapy regimens used after progression following second-line chemotherapy

From: Comparison of platinum combination re-challenge therapy and docetaxel monotherapy in non-small cell lung cancer patients previously treated with platinum-based chemoradiotherapy

  Platinum combination therapy Docetaxel monotherapy
  Third-line ≥Fourth-line Third-line ≥Fourth-line
EGFR-TKI
Gefitinib 1 1 11 5
Erlotinib 2 0 5 7
Single agent
Docetaxel 0 1 - 1
Pemetrexed 2 0 2 3
Amrubicin 2 1 8 11
Gemcitabine 0 1 16 8
S1 0 0 5 12
Others 2 0 1 5
Platinum combination 3 0 0 5
Investigational agent 0 0 1 4
  1. Abbreviations: EGFR-TKI, epidermal growth factor receptor tyrosine kinase inhibitor.